Free Trial

Annexon (ANNX) Stock Price, News & Analysis

+0.32 (+5.45%)
(As of 02:09 PM ET)
Today's Range
50-Day Range
52-Week Range
1.45 million shs
Average Volume
2.15 million shs
Market Capitalization
$572.02 million
P/E Ratio
Dividend Yield
Price Target

Annexon MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
162.6% Upside
$15.33 Price Target
Short Interest
5.58% of Shares Sold Short
Dividend Strength
News Sentiment
0.02mentions of Annexon in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$16,000 Bought Last Quarter
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

596th out of 897 stocks

Pharmaceutical Preparations Industry

280th out of 426 stocks

ANNX stock logo

About Annexon Stock (NASDAQ:ANNX)

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ANNX Stock Price History

ANNX Stock News Headlines

Annexon (NASDAQ:ANNX) Trading 3.9% Higher
What comes next after the attempt on Trump's life...
After this weekend’s attempt on Trump's life... it seems all but a lock for him to return to the White House. Now "only an ‘October Surprise’ can swing the presidential election," writes Doug Schoen, of The Hill.
Annexon, Inc. (NASDAQ:ANNX) Short Interest Up 27.4% in June
What comes next after the attempt on Trump's life...
After this weekend’s attempt on Trump's life... it seems all but a lock for him to return to the White House. Now "only an ‘October Surprise’ can swing the presidential election," writes Doug Schoen, of The Hill.
See More Headlines
Receive ANNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$3.20 per share


Free Float
Market Cap
$561.85 million
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

ANNX Stock Analysis - Frequently Asked Questions

How have ANNX shares performed this year?

Annexon's stock was trading at $4.54 at the beginning of the year. Since then, ANNX stock has increased by 28.6% and is now trading at $5.84.
View the best growth stocks for 2024 here

How were Annexon's earnings last quarter?

Annexon, Inc. (NASDAQ:ANNX) released its earnings results on Monday, May, 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.11.

When did Annexon IPO?

Annexon (ANNX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen acted as the underwriters for the IPO.

Who are Annexon's major shareholders?

Top institutional shareholders of Annexon include Hennion & Walsh Asset Management Inc. (0.21%), DNB Asset Management AS (0.05%), SG Americas Securities LLC (0.02%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Bain Capital Life Sciences Inv, Douglas Love, Michael Overdorf, Jennifer Lew, William H Carson and Ted Yednock.
View institutional ownership trends

How do I buy shares of Annexon?

Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Annexon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ) and RTX (RTX).

This page (NASDAQ:ANNX) was last updated on 7/24/2024 by Staff

From Our Partners